Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alto Neuroscience
Biotech
Alto’s phase 2 depression trial misses primary efficacy endpoint
Patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo.
Nick Paul Taylor
Jun 26, 2025 9:28am
Boehringer's schizophrenia drug fails trio of phase 3 trials
Jan 16, 2025 11:58am
Alto's midphase depression trial falls flat
Oct 23, 2024 4:47am
CRISPR Tx, Novartis, Cour & more—Chutes & Ladders
May 24, 2024 8:30am
Biogen CMO heads for the exits
Mar 15, 2024 10:51am
Alto, Fractyl head to public markets with IPOs north of $100M
Feb 2, 2024 8:14am
